For dementia, common painkillers may work best: study

by Marlowe Hood

Ordinary painkillers such as paracetamol may work better than the risky antipyschotic drugs often prescribed to calm agitation in people with dementia, according to a study released Monday.

Patients with severe dementia showed significantly less agitation when taking ordinary pain medicines than a given standard treatment, showed the study, published online by the British Medical Journal.

Extreme aggression and agitation are common symptoms of advanced dementia, including Alzheimer's disease.

Such behaviour is distressing both for patient and family members, and a serious challenge to professional caregivers.

The condition is usually compounded by pain, and the frequent inability of the persons afflicted to clearly express the nature of their discomfort.

Powerful antipsychotics and antidepressants are often the drugs of first choice and, in many countries, are prescribed for agitation to around half of dementia patients in nursing homes.

Such treatment can be dangerous: In a population of about 180,000 in Britain given antipsychotics, for example, there are 1,620 excess strokes and 1,800 excess deaths per year, according to a recent study.

"These figures emphasise the importance of finding safe and effective ways to reduce agitation and aggression in people with dementia," the researchers said.

Remarkably, little research has explored the effectiveness of off-the-shelf pain pills and other proven pain-relief drugs in quelling these common and debilitating symptoms.

To find out just how well they might work, a team of scientists led by Dag Aarsland, a professor at the Karolinska Institute in Stockholm, treated 352 patients from 16 Norwegian -- all with severe dementia, most in their mid-to-late 80s -- with one of four pain-relief medications.

Over a period of eight weeks, 70 percent took a large daily dose of paracetamol and 20 percent were given , a semi-synthetic used to treat addiction and moderate-to-acute pain.

The other 10 percent took stronger , either morphine or pregabalin, an anti-convulsant.

A control group continued their usual treatment, including certain or anti-depressants.

Experts who did not know which patients had taken which drugs did interviews during the trial and a four-week follow up.

"The intervention produced a clinically and statistically significant reduction in agitation and pain," note Paul Rosenberg and Constantine Lyketsos, professors at John Hopkins University, in a commentary also published in the .

The treatment "should give clinicians a new strategy for tackling agitation in subgroups of patients," they said.

Aarsland urged other researchers to confirm the findings in further studies.

Thirty-five million people worldwide have dementia, a number expected to more than triple by 2050 as populations across the planet age.

In Alzheimer's, the most common form of , unwanted proteins form plaque in some areas of the brain, ultimately destroying neurons and leading to irreversible brain damage.

Typical symptoms are memory loss, erratic behaviour and, in advanced stages, extreme agitation.

Alzheimer's affects 13 percent of people over 65, and up to 50 percent of those over 85.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

US orders farms to report pig virus infections

17 hours ago

The U.S. government is starting a new program to help monitor and possibly control the spread of a virus that has killed millions of pigs since showing up in the country last year.

Foreigner dies of MERS in Saudi

18 hours ago

A foreigner has died after she contracted MERS in the Saudi capital, the health ministry said on announced Friday, bringing the nationwide death toll to 73.

Vietnam battles fatal measles outbreak

21 hours ago

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

New clues on tissue scarring in scleroderma

22 hours ago

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

User comments